摘要
目的 观察吉非替尼单药治疗老年人晚期非小细胞肺癌的疗效和不良反应.方法 老年晚期非小细胞肺癌患者30例,采用口服吉非替尼治疗,250 mg/d,每4周为一个治疗周期.观察疗效、不良反应、生存质量.结果 30例患者,完全缓解（CR）0例,部分缓解（PR）8例（26.6%）,疾病稳定（SD）8例（26.6%）,疾病进展（PD）14例（49.6%）,疾病控制率53.3% 腺癌疾病控制率（84.0%）明显高于鳞癌（20.0%）（x2=9.125,P〈0.01） Ⅲ a期疾病控制率（100.0%）明显高于Ⅳ期（77.8%）（x2=3.879,P〈0.05） 中位无进展生存期3.8个月,中位生存期5.2个月 最常见不良反应为皮肤毒性,未观察到血液学毒性.结论 吉非替一线治疗老年人晚期非小细胞肺癌,具有良好的耐受性和有效性.
Objective To investigate the efficacy and adverse reactions of gefitinib in treatment of elderly patients with advanced non-small-cell lung cancer.Methods 30 elderly patients with advanced non-small cell lung cancer were treatment with oral gefitinib,250mg/d,every 4 weeks for a treatment period.The efficacy,adverse reactions,quality of life were observed.Results Of 30 cases,the rate of complete response（CR） ,partial response（PR）, stability of disease（SD） .progression of disease（PD） and disease control was 0.0% ,26.6% ,26.6% ,49.6% ,53.3% ,respectively The disease control rate（ 84.0% ） in adenocarcinoma was significantly higher than that in squamous cell carcinoma（ 20.0% ） （x2 = 9.125, P 〈 0.01） The disease control rate （100.0% ） in stage- Ⅲ was significantly higher than that in stage Ⅳ（77.8%）（x2 =3.879,P〈0.05） The median progression-free survival was 3.8 months, and median survival was 5.2 months The most common toxicity was skin toxicity, hematologic toxicity was not observed.Conclusion As the first-line treatment for advanced NSCLC, gefitinib was effective and tolerable for the elderly.
出处
《中国基层医药》
CAS
2011年第12期1625-1626,共2页
Chinese Journal of Primary Medicine and Pharmacy
